Mediwelcome Healthcare Management & Technology Inc. (HK:2159)
:2159
Want to see HK:2159 full AI Analyst Report?
Top Page
Mediwelcome Healthcare Management & Technology Inc.
(2159)
Select Model
Select Model
Rating:50Neutral
Price Target:
HK$1.50
▲(20.97% Upside)
Action:ReiteratedDate:04/27/26
The score is primarily driven by a 2025 financial turnaround with strong revenue growth and improved leverage, but capped by thin operating profitability and an unstable cash-flow history. Technically, the stock shows weak near-term momentum (below key moving averages and negative MACD), while valuation is moderate (P/E 24.63) with no dividend yield provided.
Positive Factors
Revenue rebound & net profitability
A 48% revenue increase and return to net profit in 2025 indicate the business can regain growth and monetize its offerings. Sustained top-line momentum and positive net margins provide a foundation to scale operations and invest in product and sales capabilities over the medium term.
Negative Factors
Very thin operating margins
An operating margin below 1% leaves limited buffer for cost inflation, competitive pricing pressure, or investment needs. Persistently thin margins constrain free cash flow upside and make long-term profitability highly sensitive to small adverse changes in revenue or costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound & net profitability
A 48% revenue increase and return to net profit in 2025 indicate the business can regain growth and monetize its offerings. Sustained top-line momentum and positive net margins provide a foundation to scale operations and invest in product and sales capabilities over the medium term.
Read all positive factors
Mediwelcome Healthcare Management & Technology Inc. (2159) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$414.40M
Dividend YieldN/A
Average Volume (3M)143.19K
Price to Earnings (P/E)24.6
Beta (1Y)0.55
Revenue Growth46.20%
EPS GrowthN/A
CountryHK
Employees311
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.08
Shares Outstanding280,000,000
10 Day Avg. Volume118,880
30 Day Avg. Volume143,186
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)2.15
Price to Sales (P/S)0.53
P/FCF Ratio96.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mediwelcome Healthcare Management & Technology Inc. Business Overview & Revenue Model
Company Description
Mediwelcome Healthcare Management & Technology Inc. (2159) is a healthcare technology company that focuses on providing innovative management solutions and advanced technology services for the healthcare sector. The company operates across various...
Mediwelcome Healthcare Management & Technology Inc. Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
63
Positive
Cash Flow
42
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 455.91M | 321.56M | 331.31M | 323.37M | 708.36M |
| Gross Profit | 92.26M | 51.00M | 29.89M | 32.55M | 93.60M |
| EBITDA | 7.67M | -33.61M | -74.53M | -69.08M | 11.32M |
| Net Income | 9.73M | -45.24M | -94.10M | -89.20M | 4.64M |
Balance Sheet | |||||
| Total Assets | 190.57M | 194.09M | 214.32M | 317.83M | 366.70M |
| Cash, Cash Equivalents and Short-Term Investments | 99.36M | 71.66M | 80.35M | 154.02M | 174.83M |
| Total Debt | 54.49M | 47.73M | 31.13M | 26.48M | 25.18M |
| Total Liabilities | 85.14M | 120.81M | 94.35M | 116.97M | 73.21M |
| Stockholders Equity | 111.30M | 71.14M | 116.13M | 195.02M | 283.11M |
Cash Flow | |||||
| Free Cash Flow | 2.47M | -27.10M | -77.18M | -22.75M | -24.73M |
| Operating Cash Flow | 2.88M | -14.05M | -75.58M | -18.46M | 262.00K |
| Investing Cash Flow | -13.28M | -326.00K | 16.46M | -8.36M | -16.77M |
| Financing Cash Flow | 37.34M | 5.68M | 906.00K | 54.00K | 92.84M |
Mediwelcome Healthcare Management & Technology Inc. Technical Analysis
Neutral
1.24
Price Trends
1.57
Negative
1.40
Positive
1.35
Positive
Market Momentum
-0.05
Positive
37.73
Neutral
23.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2159, the sentiment is Neutral. The current price of 1.24 is below the 20-day moving average (MA) of 1.78, below the 50-day MA of 1.57, and below the 200-day MA of 1.35, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 37.73 is Neutral, neither overbought nor oversold. The STOCH value of 23.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2159.
Mediwelcome Healthcare Management & Technology Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$225.72M | -18.49 | -18.69% | ― | -4.50% | 75.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$414.40M | 24.63 | 11.07% | ― | 46.20% | ― | |
50 Neutral | HK$539.27M | -20.98 | -10.69% | 1.72% | -3.49% | -1567.01% | |
45 Neutral | HK$6.52B | -110.24 | -2.28% | ― | -4.99% | 47.18% | |
44 Neutral | HK$808.20M | -17.95 | -21.11% | ― | -7.24% | 53.79% | |
41 Neutral | HK$1.17B | -11.46 | -13.92% | ― | 10.88% | 90.15% |
* Healthcare Sector Average
HK:2159
Mediwelcome Healthcare Management & Technology Inc.
1.48
1.00
208.33%
HK:2138
EC Healthcare
0.46
-0.19
-28.91%
HK:2158
Yidu Tech, Inc.
6.12
0.20
3.38%
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
11.88
-0.12
-1.00%
HK:0401
Wanjia Group Holdings Ltd.
0.20
0.13
181.69%
HK:9686
NEUSOFT XIKANG HOLDINGS INC.
0.96
0.07
7.87%
Mediwelcome Healthcare Management & Technology Inc. Corporate Events
Mediwelcome to Acquire Mediai Technology and Raise HK$115 Million via Share Placing
Mar 30, 2026
Mediwelcome Healthcare Management Technology Inc. has agreed to acquire 100% of Mediai Technology Development Limited for HK$139.77 million, to be settled in cash and a promissory note, marking a major transaction under Hong Kong listing rules. T...
Mediwelcome Swings to Profit on Revenue Surge and Impairment Reversal
Mar 23, 2026
Mediwelcome Healthcare Management Technology Inc. reported a sharp rebound in performance for the year ended 31 December 2025, with revenue rising to RMB468.0 million from RMB321.6 million and gross profit nearly doubling to RMB94.7 million. The ...
Mediwelcome Plans Governance Overhaul to Align With New HK Listing Rules
Mar 23, 2026
Mediwelcome Healthcare Management Technology Inc. plans to amend its memorandum and articles of association to align its corporate governance framework with updated Hong Kong listing and regulatory requirements. The board has proposed adopting a ...
Mediwelcome Flags Significantly Narrowed 2025 Loss on Higher-Margin Focus
Mar 12, 2026
Mediwelcome Healthcare Management Technology Inc. has warned investors that, while it still expects to post a loss for the year ended 31 December 2025, the deficit should narrow significantly compared with 2024. The improvement is attributed to s...
Mediwelcome Sets March 2026 Board Meeting to Review 2025 Results and Dividend
Mar 11, 2026
Mediwelcome Healthcare Management Technology Inc. has scheduled a board meeting for March 23, 2026, to review and approve its annual results for the year ended December 31, 2025, and to consider the proposed publication of those results. The boar...
Mediwelcome Reshuffles Company Secretary and Authorized Representatives
Feb 23, 2026
Mediwelcome Healthcare Management Technology Inc. has announced a series of senior corporate governance changes effective 23 February 2026, including the resignation of company secretary and authorized representative Ms. Tsoi Siu Wai, who is also...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.